AR029091A1 - Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda) - Google Patents

Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda)

Info

Publication number
AR029091A1
AR029091A1 ARP010102344A ARP010102344A AR029091A1 AR 029091 A1 AR029091 A1 AR 029091A1 AR P010102344 A ARP010102344 A AR P010102344A AR P010102344 A ARP010102344 A AR P010102344A AR 029091 A1 AR029091 A1 AR 029091A1
Authority
AR
Argentina
Prior art keywords
amino
phenylpentane
nmda
aspartate
methyl
Prior art date
Application number
ARP010102344A
Other languages
English (en)
Inventor
Englberger Werner Dr
Sundermann Bernd Dr
Sirrenberg Christian Dr
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR029091A1 publication Critical patent/AR029091A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se refiere al uso de al menos un compuesto de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol y/o de sus enantiomeros y/o uno de sus diastereomeros y/o una de sus sales fisiologicamente tolerables para la preparacion de un medicamento con efecto antagonista de N-metil-D-aspartato- (NMDA).
ARP010102344A 2000-05-22 2001-05-17 Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda) AR029091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10025238A DE10025238A1 (de) 2000-05-22 2000-05-22 Verwendung substituierter 1-Amino-5-phenylpentan-3-ol- und/oder 1-Amino-6-phenylhexan-3-ol- Verbindungen als Arzneimittel

Publications (1)

Publication Number Publication Date
AR029091A1 true AR029091A1 (es) 2003-06-04

Family

ID=7643080

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102344A AR029091A1 (es) 2000-05-22 2001-05-17 Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda)

Country Status (16)

Country Link
US (1) US6784175B2 (es)
EP (1) EP1289514B1 (es)
JP (1) JP2004509842A (es)
AR (1) AR029091A1 (es)
AT (1) ATE281158T1 (es)
AU (2) AU2001274022B2 (es)
CA (1) CA2406198A1 (es)
DE (2) DE10025238A1 (es)
ES (1) ES2231502T3 (es)
HU (1) HUP0301884A2 (es)
MX (1) MXPA02011410A (es)
NZ (1) NZ521439A (es)
PE (1) PE20011261A1 (es)
PT (1) PT1289514E (es)
UY (1) UY26718A1 (es)
WO (1) WO2001089505A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6856700B1 (en) * 2000-05-24 2005-02-15 Microsoft Corporation Palettized image compression
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
EA017264B1 (ru) * 2005-09-28 2012-11-30 Аурис Медикаль Аг Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха
WO2012009258A2 (en) * 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
EP2790686B1 (en) 2011-12-12 2021-03-10 Zilentin Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017637A (en) 1973-03-26 1977-04-12 American Home Products Corporation Benzylamine analgesics
US4155935A (en) * 1973-03-26 1979-05-22 American Home Products Corporation Benzylamine analgesics
US4366172A (en) * 1977-09-29 1982-12-28 The Upjohn Company 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use
IE913279A1 (en) 1990-09-26 1992-04-08 Astra Ab (2-Thienyl)alkylamine Derivatives Having Neuroprotective¹Properties
DE19915601A1 (de) * 1999-04-07 2000-10-19 Gruenenthal Gmbh 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung

Also Published As

Publication number Publication date
US20030181450A1 (en) 2003-09-25
AU2001274022B2 (en) 2004-10-14
CA2406198A1 (en) 2002-10-16
PT1289514E (pt) 2005-02-28
DE10025238A1 (de) 2001-11-29
HUP0301884A2 (hu) 2003-09-29
ATE281158T1 (de) 2004-11-15
MXPA02011410A (es) 2003-06-06
EP1289514B1 (de) 2004-11-03
UY26718A1 (es) 2001-06-29
DE50104405D1 (de) 2004-12-09
US6784175B2 (en) 2004-08-31
WO2001089505A1 (de) 2001-11-29
JP2004509842A (ja) 2004-04-02
PE20011261A1 (es) 2002-01-26
ES2231502T3 (es) 2005-05-16
EP1289514A1 (de) 2003-03-12
AU7402201A (en) 2001-12-03
NZ521439A (en) 2005-06-24

Similar Documents

Publication Publication Date Title
ES2545205T3 (es) Combinación de azelastina y ciclesonida
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
HN2003000054A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo (cetpi), a procedimientos de uso y a procedimientos de preparacion de las mismas.
CR7820A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
UY28001A1 (es) Derivados de azol-pirimidina condensados
AR030857A1 (es) Derivados nitroso de difenolaminas, composiciones farmaceuticas que los contienen y su uso en la preparacion de productos medicinales
UY28348A1 (es) Compuestos novedosos
ECSP088296A (es) Compuestos terapéuticos
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
HN2002000198A (es) Composiciones farmaceuticas de amlodipina y atorvastatina
HN2003000183A (es) Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
ECSP066291A (es) Sistemas emulsionantes que contienen derivados de azetidina
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
BRPI0415053A (pt) inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
HN2001000235A (es) Derivados puentes de piperazina
BR0112847A (pt) Uso de uma forma de dosagem sólida
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
AR029091A1 (es) Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda)
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
AR114270A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmacéutico
UY27620A1 (es) Ambroxoll para el tratamiento de dolores crónicos
AR028970A1 (es) USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
ITRM20030074A0 (it) Formulazioni semisolide a rilascio immediato intese per la somministrazione orale di farmaci.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal